Like the VA, Renalytix, co-founded by nephrologists, is committed to promoting kidney health vs. just managing kidney disease. Our laboratory-developed test (LDT), KidneyIntelXTM, has been validated in two large cohorts to be a highly reliable, bioprognosticTM methodology that yields a simple-to-understand, custom risk score, predicting which veteran patients with type 2 diabetes and with chronic kidney disease stages 1-3b are at low, intermediate or high risk for rapid progressive decline in kidney function.
When VA clinicians combine information gathered through KidneyIntelX with newer cardio- and reno-protective therapies, it’s a win-win. They will know which veteran patients are at higher to lower risk for rapid progressive decline in kidney function, and therefore, can implement precision medicine by appropriately targeting resources and guideline-recommended treatment plans to advance kidney health.
Our strategic approach is in line with the key pillars of the already-established Veteran’s Health Administration Directive 1053, including the VA’s recommendation to use a validated risk prediction model as a clinical decision support aid in the management of patients with CKD.
“We suggest the use of a validated risk prediction model as a clinical decision support aid in the management of patients with chronic kidney disease.”
2019 VA/DoD Clinical Practice Guideline
Management of CKD Recommendations